rozanolixizumab: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
rozanolixizumab: clinical details
Prescribing considerations
- Initiate and supervise treatment through clinicians experienced in neuromuscular or neuroinflammatory disorders.
- Assess for clinically important active infection and review vaccination requirements before starting.
- Impending or established myasthenic crisis has not been studied; consider sequencing and interactions of established crisis treatments.
- Record product name and batch number to maintain biological traceability.
- Restrict use in hyperprolinaemia to circumstances where no alternative is available.
Contraindications and cautions
- Hypersensitivity to rozanolixizumab or any excipient.
- Do not initiate during a clinically important active infection until it has resolved or been adequately treated.
- Use particular caution where evidence is limited, including severe renal impairment, hepatic impairment, pregnancy and people under 18 years.
Monitoring
- Monitor clinically for infection during treatment and consider withholding treatment if a clinically important infection develops.
- Observe for hypersensitivity during and after administration, particularly early in treatment.
- Investigate headache with fever, neck stiffness, nausea or vomiting for possible aseptic meningitis.
- Review clinical response and possible attenuated effects of concomitant IgG-based treatments.
- Report suspected adverse reactions through the MHRA Yellow Card Scheme.
Clinical pharmacology
Rozanolixizumab is a humanised IgG4 monoclonal antibody that blocks FcRn-mediated IgG recycling. It lowers total and pathogenic IgG without a clinically relevant effect on albumin. It has target-mediated nonlinear pharmacokinetics and is expected to undergo catabolic degradation to peptides and amino acids.
Formulation and product differences
- Supplied as a ready-to-use solution for subcutaneous infusion in single-use vials of several fill volumes; not all presentations may be marketed.
- The solution should be clear to slightly opalescent and colourless to pale brownish-yellow.
- Administration may use a compatible infusion pump or manual syringe push after appropriate training.
- The product must not be mixed with other infusion medicines and administration equipment containing DEHP should not be used.
rozanolixizumab preparations and strengths
Injection
Route: Parenteral
Strengths: 140 mg/mL
rozanolixizumab interactions
Formal interaction studies have not been performed. Important mechanism-based interactions include:
IgG-based treatments, including monoclonal antibodies and intravenous immunoglobulin
Rozanolixizumab may lower their circulating concentrations and reduce their effect, so specialist scheduling and efficacy monitoring are needed.
Fc–peptide fusion proteins
Circulating concentrations and clinical effect may be reduced through interference with FcRn recycling.
Intravenous or subcutaneous immunoglobulin, plasma exchange, plasmapheresis or immunoadsorption
These treatments may reduce circulating rozanolixizumab concentrations.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.